The a16z Show

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio) The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, MIT economist Andrew Lo and a16z General Partner on the Bio Fund Jorge Conde discuss how exactly we place an economic value on a cure; the questions we still need to figure out, like who should pay for what and how; and how we need to start thinking about handling the coming influx of highly priced medicines like these into our healthcare system. If we think about these payments as a kind of 'mortgage for a cure,' what happens when your gene therapy mortgage defaults? How would payment plans like these move between insurance plans? Lo and Conde also discuss the broader context in our healthcare system, the economics and risk of drug discovery and development overall – and finally, how our markets might just function more like biological systems than anything else. Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.